| Literature DB >> 19633015 |
Vinzenz Hombach1, Nico Merkle, Jan Torzewski, Johann M Kraus, Markus Kunze, Oliver Zimmermann, Hans A Kestler, Jochen Wöhrle.
Abstract
AIMS: Clinical parameters are weak predictors of outcome in patients with idiopathic dilated cardiomyopathy (IDC). We assessed the prognostic value of cardiac magnetic resonance (CMR) parameters in addition to conventional clinical and electrocardiographic characteristics. METHODS ANDEntities:
Mesh:
Year: 2009 PMID: 19633015 PMCID: PMC2726960 DOI: 10.1093/eurheartj/ehp293
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Patient characteristics
| All patients | With LGE | No LGE | |
|---|---|---|---|
| 141 | 36 | 105 | |
| Male, | 108 (76.6) | 30 (83.3) | 78 (25.7) |
| Female, | 33 (23.4) | 6 (16.7) | 27 (25.7) |
| Age (years) | 56.1 ± 13.3 | 59.7 ± 11.2 | 54.8 ± 13.8 |
| Cardiovascular risk factors, | |||
| Diabetes mellitus | 23 (16.3) | 9 (25.0) | 14 (13.3) |
| Arterial hypertension | 55 (39.0) | 13 (36.1) | 42 (40.0) |
| Hypercholesterolemia | 53 (37.6) | 14 (38.9) | 39 (37.1) |
| Smoking | 41 (27.5) | 12 (30) | 29 (26.6) |
| Familial disposition | 21 (14.9) | 8 (22.2) | 13 (12.4) |
| BMI (kg/m2) | 26.7 ± 4.9 | 26.4 ± 4.3 | 26.8 ± 5.1 |
| NYHA class I, | 17 (12.1) | 5 (13.9) | 12 (11.4) |
| NYHA class II, | 16 (11.3) | 4 (11.1) | 12 (11.4) |
| NYHA class III, | 65 (46.1) | 17 (47.2) | 48 (45.7) |
| NYHA class IV, | 43 (30.5) | 10 (27.8) | 33 (31.4) |
| QRS >110 ms | 94 (66.7) | 29 (80.6) | 65 (61.9) |
| QTc >440 ms | 65 (46.1) | 18 (50.0) | 47 (44.8) |
| ACE-inhibitor, | 123 (87.2) | 33 (91.7) | 90 (85.7) |
| Beta-blocker, | 127 (90.1) | 33 (91.7) | 94 (89.5) |
| Spironolactone, | 105 (74.5) | 28 (77.8) | 77 (73.3) |
| Diuretic, | 127 (90.1) | 32 (88.9) | 95 (90.5) |
| Phenprocoumone, | 69 (48.9) | 23 (63.9) | 46 (43.8) |
BMI, body mass index; NYHA, New York Heart Association; ACE, angiotensin-converting enzyme.
Cardiac magnetic resonance imaging characteristics
| All patients | With LGE | No LGE | |
|---|---|---|---|
| 141 | 36 | 105 | |
| LVEDV (mL) | 271 ± 104 | 282 ± 88 | 268 ± 108 |
| LVESV (mL) | 194 ± 103 | 209 ± 89 | 189 ± 108 |
| LVEF (%) | 32 ± 14 | 28 ± 12 | 34 ± 15 |
| CI (L/min/m2) | 2.76 ± 0.79 | 2.53 ± 0.71 | 2.84 ± 0.80 |
| LVEDVI (mL/m2) | 141 ± 56 | 150 ± 49 | 139 ± 58 |
| LVESVI (mL/m2) | 101 ± 56 | 111 ± 48 | 98 ± 59 |
| RVEDV (mL) | 166 ± 58 | 182 ± 65 | 161 ± 55 |
| RVESV (mL) | 90 ± 55 | 108 ± 62 | 84 ± 51 |
| RVEF (%) | 50 ± 16 | 43 ± 16 | 52 ± 15 |
| RVEDVI (mL/m2) | 87 ± 33 | 94 ± 32 | 85 ± 33 |
| RVESVI (mL/m2) | 47 ± 29 | 58 ± 33 | 43 ± 27 |
| Heart rate (b.p.m.) | 71 ± 14 | 69 ± 15 | 72 ± 14 |
EDV, end-diastolic volume; ESV, end-systolic volume; EDVI, end-diastolic volume index; ESVI, end-systolic volume index.
Univariate and multivariable analyses for predictors of primary endpoint
| Univariate analysis | Multivariable analysis | Resampling procedure | |||
|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | Frequency | |||
| Diabetes | 4.38 (1.98–9.66) | <0.001 | 3.19 (1.40–7.29) | 0.006 | 0.90 |
| QRS >110 ms | 5.43 (1.28–23.1) | 0.022 | 4.64 (1.04–20.78) | 0.045 | 0.71 |
| QTc >440 ms | 1.57 (0.71–3.5) | 0.261 | |||
| LVEDVI | 1.00 (1.00–1.01) | 0.238 | |||
| RVEDVI | 1.01 (1.00–1.02) | 0.003 | 1.01 (1.00–1.02) | 0.006 | 0.76 |
| CI | 0.45 (0.25–0.83) | 0.010 | 0.35 (0.19–0.65) | <0.001 | 0.95 |
| LVEF | 0.95 (0.92–0.99) | 0.013 | 0.45 | ||
| RVEF | 0.97 (0.95–0.99) | 0.022 | 0.38 | ||
| LGE | 2.26 (1.03–4.99) | 0.043 | 0.54 | ||
Univariate and multivariable analyses for predictors of secondary endpoint
| Univariate analysis | Multivariable analysis | Resampling procedure | |||
|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | Frequency | |||
| Diabetes | 1.50 (0.79–2.85) | 0.211 | |||
| QRS >110 ms | 2.32 (1.13–4.77) | 0.022 | 2.39 (1.11–5.12) | 0.026 | 0.86 |
| QTc >440 ms | 1.74 (1.01–2.99) | 0.046 | 1.76 (1.01–3.07) | 0.047 | 0.70 |
| LVEDVI | 1.00 (1.00–1.01) | 0.009 | 0.28 | ||
| RVEDVI | 1.01 (1.00–1.02) | 0.008 | 1.01 (1.0–1.02) | 0.010 | 0.76 |
| CI | 0.72 (0.48–1.06) | 0.096 | |||
| LVEF | 0.97 (0.94–0.99) | 0.005 | 0.61 | ||
| RVEF | 0.98 (0.96–1.00) | 0.040 | 0.32 | ||
| LGE | 1.45 (0.82–2.58) | 0.202 | |||